Sangamo Therapeutics, Inc. SGMO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO

SGMO 0.438

-5.1%

11:26 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (175)	2/9/2006 3:23:44 PM
From: tnsaf	of 368

[Sangamo intends to initiate a Phase 1 clinical trial to test this HIV ZFP Therapeutic] This looks to be the only new thing in the announcement. Jason Sangamo BioSciences Announces HIV/CCR5 ZFP Therapeutic Data Presentation at 13th Conference on Retroviruses and Opportunistic Infections Thursday February 9, 1:00 pm ET Clinical Trial Expected to Begin Later This Year RICHMOND, Calif., Feb. 9 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) today announced that data from its program to develop a zinc finger DNA-binding protein (ZFP) treatment for HIV/AIDS were presented in an oral session at the 13th Conference on Retroviruses and Opportunistic Infections (CROI) held in Denver this week. The data demonstrate that Sangamo's ZFP nuclease (ZFN(TM)) technology can be used to make cells resistant to HIV infection by permanently modifying the DNA sequence encoding CCR5, an essential co-receptor for the entry of HIV into immune cells. In the second half of 2006, Sangamo intends to initiate a Phase 1 clinical trial to test this HIV ZFP Therapeutic, working in close collaboration with Dr. Carl June of the University of Pennsylvania School of Medicine. [snip]

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next